Do patients’ baseline characteristics with erectile dysfunction, predict phosphodiesterase type 5 (PDE5) inhibitors’ efficacy and patients’ preference? A comparative, randomized, open-label, crossover study.
Phase 4
Completed
- Conditions
- Erectile DysfunctionOther - Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)
- Registration Number
- ACTRN12609000921280
- Lead Sponsor
- Toutziaris Chrysovalantis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Male
- Target Recruitment
- 200
Inclusion Criteria
Erectile dysfunction for at least 6 months
Exclusion Criteria
1) Myocardial infarction until 6 months ago
2) Nitrite drug administration
3) Present urogenital infection
4) PDE 5 inhibitor intake at least 3 months before the study begins
5) Peyronie disease or other anatomic disorders of the penis
6) The existence of a serious neurological problem such as multiple sclerosis or stroke or spinal cord injury
7) The existence of erectile dysfunction <6 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method